Country, year | Residents/LTCFs (number) | Specimen type | MRSA % (range %) | ESBL % (range %) | Referencesa |
---|---|---|---|---|---|
Sweden, 2008 | 495/9 | Rectal | 0.0 | 3.0 | [54]b |
Sweden, 2010 | 163/1 | Catheter Urine | Â | 0.6 | [55] |
Sweden, 2014 | 91/10 | Rectal | Â | 11 | [56]b |
Netherlands, 2009 | 1268/12 | Nasal | 0.3 | Â | [57] |
Netherlands, 2012–14 | 4763 (MRSA), 5421 (ESBL)/107 | Nasal (MRSA) Urine (ESBL, E. coli) | 0.3 | 2.2 | [51] |
Germany, 2009 | 1827/32 | Nasal and/or wound | 7.6 (0–18.6) |  | [45] |
Germany, 2010–11 | 240/11 | Rectal |  | 9.6 (0–30) | [18] |
Germany, 2012 | 150/8 | MRSA: nasal, pharyngeal ESBL: perineal | 9.2 | 26.7 | [8] |
Germany, 2013 | 690/26 (MRSA), 455/26 (ESBL) | Nasal, pharyngeal, perineal | 6.5 | 17.8 | [7] |
Germany, 2013–14 | 2858/65 | Nasal, pharyngeal | 4.8 (0–26.7) |  | [46] |
Germany, 2013–14 | 156/31 | Rectal |  | 14.7 | [19] |
Luxembourg, 2010 | 954/19 | Nasal, pharyngeal | 7.2 (0–16) |  | [49] |
Slovenia, 2001–02 | 107/1 | Nasal and skin | 9.3 |  | [10] |
France, 2004 | 109/1 | Nasal, rectal | 37.6 | Â | [52] |
France, 2013 | 1155/38 | Rectal or urine |  | 9.9 (0.0–28.6) | [58] |
Belgium, 2005 | 2953/60 | Nasal, pharyngeal, wound, urine | 19.5 (2.0–42.9) |  | [47] |
Belgium, 2011 | 2791/60 | Nasal, pharyngeal, wound, rectal | 12.2 (0–36) | 6.2 (0–20) | [6] |
Spain, 2003 | 413/4 | Nasal, skin | 22.5 (17.2–35.5) |  | [59] |
Spain, 2005 | 1377/9 | Nasal | 16.8 (6.7–35.8) |  | [60] |
Spain, 2009–10 | 744/17 | Nasal | 19.6 |  | [61] |
UK, 2005 | 715/39 | Nasal | 22.2 (0–50) |  | [42] |
UK, 2005–07 | 3037/69 | Nasal | 20 (19–21) |  | [43] |
UK, 2006–09 | 2492/65 | Nasal | 20.5 |  | [44] |
Ireland, 2004–06 | 294/16 | Rectal (only E. coli) |  | 40.5 (0–75) | [17] |
Ireland, 2005–06 | 1111/45 | Nasal | 23.3 (0–73) |  | [9] |
Ireland, 2012–13 | 64/1 | Nasal, rectal, urine | 27 | 55 | [4]b |